ProMIS Neurosciences reports FY2025 net loss of $39.7M; Phase 1b fully enrolled, $75.5M financing closed

ProMIS Neurosciences Inc.

Net loss of $39.7M in FY2025; R&D expense soared to $33.4M from $10.6M a year ago, driven by PRECISE-AD trial.
Cash of $6.1M at Dec 31, 2025; subsequent $75.5M private placement in Feb 2026 provides cash runway through 2027.
PRECISE-AD Phase 1b enrollment completed with 144 patients; six-month blinded interim data expected early Q3 2026.
PMN310 continues to show favorable safety profile with no treatment-related SAEs reported after over 12 months of dosing.
PMN310 granted FDA Fast Track Designation in July 2025; goal to advance directly into a single registrational study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProMIS Neurosciences Inc. reported the year ended December 31, 2025 results: net income $39.7 million.

Period: the year ended December 31, 2025
Net income: $39.7 million
Result: reported results

Exact text from the filing

For the year ended December 31, 2025, the Company reported a net loss of $39.7 million

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-034162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.